TREATMENT OF NEUROLOGICAL DEFICITS IN THE STRIATUM OR SUBSTANTA NIGRA PARS COMPACTA
0 Assignments
0 Petitions
Accused Products
Abstract
The present invention is directed to methods of treating neurological deficits resulting from injury or disease to the striatum or substanta nigra pars compacta of a human by administering human recombinant GDF5 to the striatum or substanta nigra pars compacta of a human in amounts effective to induce cell populations having the capacity to differentiate towards a dopaminergic phenotype to in fact differentiate towards a dopaminergic phenotype, and to neurotrophic compositions and matrices suitable for use in such treatments.
30 Citations
25 Claims
-
1. (canceled)
-
2. (canceled)
-
3. (canceled)
-
4. (canceled)
-
5. (canceled)
-
6. (canceled)
-
7. (canceled)
-
8. (canceled)
-
9. (canceled)
-
10. (canceled)
-
11. (canceled)
-
12. (canceled)
-
13. (canceled)
-
14. (canceled)
-
15. (canceled)
-
16. (canceled)
-
17. (canceled)
-
18. (canceled)
-
19. (canceled)
-
20. (canceled)
- 21. A method for differentiating postpartum cells towards a dopaminergic phenotype, comprising treating the postpartum cells with an amount of human recombinant GDF5 effective to induce the postpartum cells to differentiate towards a dopaminergic phenotype.
Specification